Kite to manufacture CAR T-cell therapy in Europe

By The Science Advisory Board staff writers

June 12, 2020 -- Gilead subsidiary Kite has received approval from the European Medicine Agency for end-to-end manufacturing of individualized cell therapies at its European facility.

Yescarta (axicabtagene ciloleucel) was the first chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma and primary mediastinal large B-cell lymphoma. The drug is similarly approved in the European Union.

Kite
Kite's European cell therapy manufacturing facility, located outside of Amsterdam. Image courtesy of Kite.

Kite has nearly 90 treatment centers in 16 countries across Europe and Israel. The new European facility with a central location right outside of Amsterdam will reduce the delivery time to and from treatment centers. The facility has the capacity to produce therapies for up to 4,000 patients per year.

Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.
Avectas, UCD partner on cell engineering
Avectas and the Simon Laboratory at UC Davis, California (UCD) will work together on cell-engineering technology.
EdiGene, Immunochina to develop CAR-T therapy
EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.
CARsgen receives IND clearance for cell therapy
CARsgen Therapeutics has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration for a cell therapy drug for advanced...

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter